Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18”

109 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 109 results

Large-scale testing (Phase 3)Study completedNCT03493542
What this trial is testing

Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

Who this might be right for
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
Merck Sharp & Dohme LLC 766
Large-scale testing (Phase 3)WithdrawnNCT00733122
What this trial is testing

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

Who this might be right for
HPV Infections
Merck Sharp & Dohme LLC
Large-scale testing (Phase 3)Study completedNCT01047345
What this trial is testing

V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Who this might be right for
Cervical CancersVulvar CancersVaginal Cancers+1 more
Merck Sharp & Dohme LLC 924
Not applicableStudy completedNCT01077856
What this trial is testing

GARDASIL™ Vaccine Impact in Population Study (V501-033)

Who this might be right for
Human Papillomavirus Infections
Merck Sharp & Dohme LLC 54,516
Not applicableStudy completedNCT00573651
What this trial is testing

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis

Who this might be right for
Arthritis
University Hospitals Cleveland Medical Center 43
Post-approval studies (Phase 4)Active Not RecruitingNCT03023631
What this trial is testing

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Who this might be right for
Allogeneic Hematopoietic Stem Cell Transplant RecipientHematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Center 48
Post-approval studies (Phase 4)Study completedNCT03943875
What this trial is testing

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

Who this might be right for
ImmunizationEfficacyHuman Papilloma Virus
The University of Texas Medical Branch, Galveston 767
Not applicableStudy completedNCT01924754
What this trial is testing

Gardasil Immunogenicity With Needle-Free Injection

Who this might be right for
HPV Seroconversion
University of California, San Francisco 150
Large-scale testing (Phase 3)Study completedNCT00092495
What this trial is testing

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Who this might be right for
Cervical CancerGenital Warts
Merck Sharp & Dohme LLC 3,055
Large-scale testing (Phase 3)Study completedNCT02993757
What this trial is testing

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Who this might be right for
Dengue FeverDengue Hemorrhagic FeverHuman Papillomavirus Disease
Sanofi Pasteur, a Sanofi Company 528
Not applicableStudy completedNCT01702337
What this trial is testing

Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

Who this might be right for
Human Papillomavirus Infection
GlaxoSmithKline 1
Testing effectiveness (Phase 2)Study completedNCT00411749
What this trial is testing

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Who this might be right for
HPV Infections
Merck Sharp & Dohme LLC 107
Early research (Phase 1)Study completedNCT00851643
What this trial is testing

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Who this might be right for
Human Papilloma VirusCervical CancerVulvar Cancer+2 more
Merck Sharp & Dohme LLC 158
Testing effectiveness (Phase 2)Study completedNCT00551187
What this trial is testing

Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Who this might be right for
Cervical CancerVulvar CancerVaginal Cancer+2 more
Merck Sharp & Dohme LLC 620
Very early researchActive Not RecruitingNCT05329961
What this trial is testing

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old

Who this might be right for
Human Papilloma Virus
Boston Medical Center 155
Large-scale testing (Phase 3)Study completedNCT00325130
What this trial is testing

Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)

Who this might be right for
Neoplasms, Glandular and EpithelialDiphtheriaTetanus+2 more
Merck Sharp & Dohme LLC 1,042
Large-scale testing (Phase 3)Study completedNCT01462357
What this trial is testing

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Who this might be right for
Infections, Papillomavirus
GlaxoSmithKline 1,079
Not applicableStudy completedNCT03083249
What this trial is testing

Gardasil Knowledge

Who this might be right for
HPV
Sarah Hostetter, MD 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339163
What this trial is testing

Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*

Who this might be right for
Recurrent Respiratory Papillomatosis (RRP)
Ohio State University 50
Not applicableStudy completedNCT01299714
What this trial is testing

Community Awareness, Resources and Education (CARE II): Project 3

Who this might be right for
Uterine Cervical Cancer
Ohio State University Comprehensive Cancer Center 191
Load More Results